Novo Nordisk more than doubles 2025 obesity sales goal

Danish pharmaceutical firm Novo Nordisk has upgraded its sales predictions for its weight loss products after 78-percent growth in Q4.

Photo: Novo Nordisk / PR

Novo Nordisk has more than doubled its goal for the sales of its obesity drugs, now aiming for over DKK 25bn (USD 3.7bn) in sales in 2025.

Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest revealed this at the company’s capital markets day on March 3.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs